

DESCRIPTION

Source Mouse myeloma cell line, NS0-derived
Gln21-Asn200 with a C-terminal 10 His tag
Accession # P11672

N-terminal Sequence Analysis No results obtained: Gln21 predicted

Predicted Molecular Mass 22 kDa

SPECIFICATIONS

SDS-PAGE 26-27 kDa doublet, reducing conditions

Activity Measured by its ability to bind Iron(III) dihydroxybenzoic acid [Fe(DHBA)₃]. The binding of Fe(DHBA)₃ results in the quenching of Trp fluorescence in Lipocalin-2.
>1.0 μM of Fe(DHBA)₃ can be bound under the described conditions.

Endotoxin Level <1.0 EU per 1 μg of the protein by the LAL method.

Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Supplied as a 0.2 μm filtered solution in MES and NaCl. See Certificate of Analysis for details.

Activity Assay Protocol

- Materials**
- Assay Buffer: 50 mM Tris, 10 mM CaCl₂, 150 mM NaCl, pH 7.5 (TCN)
 - Ligand Buffer: 0.1 M Tris, pH 8.0
 - Recombinant Mouse Lipocalin-2/NGAL (rmLipocalin-2) (Catalog # 1857-LC)
 - Iron III (Fe³⁺) (Sigma, Catalog # 16596)
 - 2,3-Dihydroxybenzoic Acid (DHBA) (Sigma, Catalog # 126209)
 - F16 Black Maxisorp Plate (Nunc, Catalog #: 475515)
 - Fluorescent Plate Reader (Model: Spectramax Gemini EM by Molecular Devices) or equivalent

- Assay**
1. Prepare a curve of Fe³⁺ in deionized water with the following serial dilutions: 640, 320, 160, 80, 40, 20, 10, 5, and 2.5 μM.
 2. Prepare 1 mM DHBA in Ligand Buffer from powder stock.
 3. Combine equal volumes of the Fe³⁺ curve with 1 mM DHBA. Include a control of 1 mM DHBA and Ligand Buffer.
 4. Incubate at room temperature for 10 minutes.
 5. After incubation, perform 5 fold dilutions to the curve with Assay Buffer.
 6. Dilute rmLipocalin-2 (MW: 21905 Da) to 4 μM in Assay Buffer.
 7. In a plate, load 50 μL of the diluted Fe(DHBA)₃ complex curve and 50 μL of 4 μM rmLipocalin-2.
 8. Incubate reaction at room temperature for 30 minutes.
 9. Read at excitation and emission wavelengths of 280 nM and 340 nM, respectively in endpoint mode.
 10. Plot a 4-parameter curve of Fe(DHBA)₃ concentration (x-axis) versus RFUs (y-axis), and calculate a BC₅₀ from the curve.

- Final Assay Conditions** Per Well:
- Fe(DHBA)₃ complex: 0.125, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16, and 32 μM.
 - rmLipocalin-2: 2 μM

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

- Stability & Storage** Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 6 months from date of receipt, -20 to -70 °C as supplied.
 - 3 months, -20 to -70 °C under sterile conditions after opening.

BACKGROUND

Mouse Lipocalin-2 was cloned from mouse kidney cells (1). Its very high level of expression at the post-stratum uterus gave it the name uterocalin (2). Lipocalin-2 has been implicated in a variety of processes including cell differentiation, tumorigenesis, and apoptosis (3-5). Studies indicate that Lipocalin-2 binds a bacterial catecholate siderophore that is bound to a ferric ion, such as enterobactin, with a subnanomolar dissociation constant ($K_D = 0.41$ nM) (6). The bound ferric enterobactin complex breaks down slowly in a month into dihydroxybenzoyl serine and dihydroxybenzoic acid (DHBA). It also binds to a ferric DHBA complex with much less K_D values (7.9 nM) (6). Secretion of Lipocalin-2 in immune cells increases in response to stimulation of Toll-like receptor as an acute phase response to infection. As a result, it acts as a potent bacteriostatic reagent by sequestering iron (7). Moreover, Lipocalin-2 can alter the invasive and metastatic behavior of Ras-transformed breast cancer cells *in vitro* and *in vivo* by reversing the epithelial to mesenchymal transition inducing activity of Ras, through restoration of E-cadherin expression, via effects on the Ras-MAPK signaling pathway (8).

References:

1. Hraba-Renevey, s. *et al.* (1989) *Oncogene*. **4**:601.
2. Liu, Q. *et al.* (1993) *Mol Reprod Dev*. **46**:507.
3. Kjeldsen L, *et al.* (2000) *Biochim Biophys Acta*. **1482**:272.
4. Devireddy, L.R. *et al.* (2001) *Science* **293**:829.
5. Yang, M.B. *et al.* (2002) *Mol. Cell*. **10**:1045.
6. Goetz, D.H. *et al.* (2002) *Mol. Cell* **10**:1033.
7. Flo, T.H. *et al.* (2004) *Nature* **432**:917.
8. Hanai, J. *et al.* (2005) *J. Biol. Chem.* **280**:13641.